168 related articles for article (PubMed ID: 31646247)
21. Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure-Activity Relationships.
Hu K; Zhu Z; Mathahs MM; Tran H; Bommer J; Testa CA; Schmidt WN
Drug Des Devel Ther; 2020; 14():757-771. PubMed ID: 32158194
[TBL] [Abstract][Full Text] [Related]
22. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
He Y; King MS; Kempf DJ; Lu L; Lim HB; Krishnan P; Kati W; Middleton T; Molla A
Antimicrob Agents Chemother; 2008 Mar; 52(3):1101-10. PubMed ID: 18086851
[TBL] [Abstract][Full Text] [Related]
23. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.
Romano KP; Ali A; Aydin C; Soumana D; Ozen A; Deveau LM; Silver C; Cao H; Newton A; Petropoulos CJ; Huang W; Schiffer CA
PLoS Pathog; 2012; 8(7):e1002832. PubMed ID: 22910833
[TBL] [Abstract][Full Text] [Related]
24. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance.
Ali A; Aydin C; Gildemeister R; Romano KP; Cao H; Ozen A; Soumana D; Newton A; Petropoulos CJ; Huang W; Schiffer CA
ACS Chem Biol; 2013 Jul; 8(7):1469-78. PubMed ID: 23594083
[TBL] [Abstract][Full Text] [Related]
25. Unexpected Replication Boost by Simeprevir for Simeprevir-Resistant Variants in Genotype 1a Hepatitis C Virus.
Murai K; Shimakami T; Welsch C; Shirasaki T; Liu F; Kitabayashi J; Tanaka S; Funaki M; Omura H; Nishikawa T; Sumiyadorj A; Honda M; Kaneko S
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661883
[TBL] [Abstract][Full Text] [Related]
26. Identification of non-macrocyclic small molecule inhibitors against the NS3/4A serine protease of hepatitis C virus through in silico screening.
Chaudhuri R; Lee H; Truong L; Torres J; Patel K; Johnson ME
J Chem Inf Model; 2012 Aug; 52(8):2245-56. PubMed ID: 22697413
[TBL] [Abstract][Full Text] [Related]
27. Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a.
Guo Z; Black S; Hu Y; McMonagle P; Ingravallo P; Chase R; Curry S; Asante-Appiah E
J Biol Chem; 2017 Apr; 292(15):6202-6212. PubMed ID: 28228479
[TBL] [Abstract][Full Text] [Related]
28. Development of cell-based assays for in vitro characterization of hepatitis C virus NS3/4A protease inhibitors.
Chung V; Carroll AR; Gray NM; Parry NR; Thommes PA; Viner KC; D'Souza EA
Antimicrob Agents Chemother; 2005 Apr; 49(4):1381-90. PubMed ID: 15793116
[TBL] [Abstract][Full Text] [Related]
29. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.
Ren J; Ojeda I; Patel M; Johnson ME; Lee H
Bioorg Med Chem Lett; 2019 Aug; 29(16):2349-2353. PubMed ID: 31201062
[TBL] [Abstract][Full Text] [Related]
30. Structural Similarity of SARS-CoV2 M
Bafna K; Krug RM; Montelione GT
ChemRxiv; 2020 Apr; ():. PubMed ID: 32511291
[TBL] [Abstract][Full Text] [Related]
31. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
[TBL] [Abstract][Full Text] [Related]
32. The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
Lahser FC; Bystol K; Curry S; McMonagle P; Xia E; Ingravallo P; Chase R; Liu R; Black T; Hazuda D; Howe AY; Asante-Appiah E
Antimicrob Agents Chemother; 2016 May; 60(5):2954-64. PubMed ID: 26926625
[TBL] [Abstract][Full Text] [Related]
33. Screening and identification of bioactive compounds from citrus against non-structural protein 3 protease of hepatitis C virus genotype 3a by fluorescence resonance energy transfer assay and mass spectrometry.
Khan M; Rauf W; Habib FE; Rahman M; Iqbal M
World J Hepatol; 2020 Nov; 12(11):976-992. PubMed ID: 33312423
[TBL] [Abstract][Full Text] [Related]
34. Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach.
Palanisamy N; Lennerstrand J
Interdiscip Sci; 2018 Mar; 10(1):143-156. PubMed ID: 27311576
[TBL] [Abstract][Full Text] [Related]
35. Investigation of some benzoquinazoline and quinazoline derivatives as novel inhibitors of HCV-NS3/4A protease: biological, molecular docking and QSAR studies.
Abuelizz HA; Marzouk M; Bakheit AH; Al-Salahi R
RSC Adv; 2020 Sep; 10(59):35820-35830. PubMed ID: 35517076
[TBL] [Abstract][Full Text] [Related]
36. Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase?
Zhu Z; Wilson AT; Luxon BA; Brown KE; Mathahs MM; Bandyopadhyay S; McCaffrey AP; Schmidt WN
Hepatology; 2010 Dec; 52(6):1897-905. PubMed ID: 21105106
[TBL] [Abstract][Full Text] [Related]
37. A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants.
Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Gursky VV; Samsonova MG; Samsonov AM; Clausznitzer D; Kaderali L; Kolchanov NA; Ivanisenko VA
PLoS One; 2014; 9(3):e91502. PubMed ID: 24643004
[TBL] [Abstract][Full Text] [Related]
38. Establishment and application of high throughput screening model for hepatitis C virus NS3-4A protease inhibitors in vitro.
Jian-rui L; Yan-bin W; Shu-yi S; Hong-shan C; Jian-dong J; Zong-gen B
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Feb; 33(1):98-101. PubMed ID: 21375947
[TBL] [Abstract][Full Text] [Related]
39. Novel peptidyl α-aminoalkylphosphonates as inhibitors of hepatitis C virus NS3/4A protease.
Skoreński M; Pachota M; Pyrć K; Sieńczyk M; Oleksyszyn J
Antiviral Res; 2017 Aug; 144():286-298. PubMed ID: 28673801
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
